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Abstract 
Background 
The 69th World Health Assembly passed a resolution to eliminate hepatitis C virus (HCV) 
infection by 2030, which can become a reality with the recent launch of the direct acting 
antiviral therapies. Reliable disease burden estimates are required for national strategies. 
This analysis estimates the global prevalence of viremic HCV at the end of 2015, an 
update of the 2014 analysis, which reported 80 (64-103) million viremic infections in 
2013. 
 
Methodology 
We developed country level disease burden models following a systematic review of 
HCV prevalence (number of studies, n = 6,754) and genotype (n = 11,342) studies 
published after 2013. A Delphi process was used to gain country expert consensus and 
validate inputs. Published estimates alone were used for countries where expert panel 
meetings could not be scheduled. The global prevalence was estimated by using regional 
averages for countries without data. 
 
Findings 
Models were built for 100 countries, 59 of which were approved by country experts, with 
the remaining 41 estimated using published data alone. The remaining countries had 
insufficient data to create a model. The global prevalence of viremic HCV is estimated to 
be 0·96% (95% UI: 0·84-1·07%) in 2015, corresponding to 71 (62-79) million viremic 
infections. Genotypes 1 and 3 were most common (44% and 25%, respectively).  
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Interpretation 
The global estimate of viremic infections is lower than previous estimates due to more 
recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to 
liver-related causes and an aging population have contributed to a reduction in infections.  
This study was funded by the John C. Martin Foundation. 
 
Keywords: Hepatitis C, global, prevalence, genotype 
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Research in context 
Evidence before this study 
In 2014, we estimated the global HCV prevalence and genotype distribution following a 
comprehensive review of indexed sources and grey literature (e.g., government reports) 
published between 2000 and 2013. The analysis focused on quantifying the number of viremic 
infections (HCV RNA positive). Three global prevalence studies published prior to 2014 
followed a traditional systematic review and meta-analysis procedure and reported anti-HCV 
positive infections, which are serological evidence of past or present HCV infection.  
Added value of this study 
The present analysis represents both an update to and significant expansion of previous efforts to 
quantify the HCV prevalence and disease burden. A Delphi process was used to complement a 
traditional systematic review by adding a level of validation through discussions with country 
experts. In total, 400 experts were consulted to approve the inputs and outputs of 59 country 
models. This work is additionally unique in that it uses a disease burden model to forecast the 
2015 year-end HCV prevalence, accounting for the impact of a changing population due to 
aging, treatment and cure, and mortality. In total 100 countries, representing more than 85% of 
the world’s population, were included in the analysis. Data from these countries were used to 
estimate the regional prevalence, and regional prevalence rates were then applied to countries 
with missing data to estimate the global HCV prevalence. 
Implications of all the available evidence 
In 2016, the 69th World Health Assembly passed a resolution to eliminate hepatitis infection by 
2030, and the World Health Organization (WHO) introduced global targets for the care and 
management of HCV including: “a 90% reduction in new cases of chronic hepatitis C, a 65% 
reduction in hepatitis C deaths, and treatment of 80% of eligible people with chronic hepatitis C 
infections”. The global HCV prevalence rate reported in this study is much lower than previous 
estimates have suggested. While some of this decline can be attributed to more recent (lower) 
prevalence estimates in Africa, increased mortality due to liver-related causes and an aging 
population have also contributed to a reduction in infections. The dissemination of the data 
presented here is crucial for the development of national and regional strategies to achieve these 
international targets.  
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Introduction 
Hepatitis C virus (HCV) infection is of growing international concern due to its 
substantial impact on morbidity and mortality.1-6 A leading cause of cirrhosis, 
hepatocellular carcinoma (HCC), liver transplantation, and liver-related death across the 
globe, HCV-related disease burden continues to increase as the infected population 
advances to late stage liver disease.7,8 The disease inflicts an immense health and 
economic burden on countries due to the infection’s hepatic and extra-hepatic effects.9-14  
 
In 2016, the 69th World Health Assembly passed a resolution to eliminate hepatitis 
infection by 2030 15, and the World Health Organization (WHO) introduced global 
targets for the care and management of HCV including: “a 90% reduction in new cases of 
chronic hepatitis C, a 65% reduction in hepatitis C deaths, and treatment of 80% of 
eligible people with chronic hepatitis C infections”.16 To achieve these goals, countries 
need to develop national policies based on up-to-date and reliable epidemiological 
evidence.17-19 However, often data are outdated and conflicting, making evidence-based 
policymaking and resource allocation difficult. The objective of this work was to review 
and analyze available data to estimate the current HCV disease burden at the national 
level to support countries in their efforts to develop national strategies. 
 
In 2014, we estimated the global HCV prevalence and genotype distribution following a 
comprehensive review of indexed sources and grey literature (e.g., government reports) 
published between 2000 and 2013.20 The analysis focused on quantifying the number of 
viremic infections (HCV RNA positive). In comparison, earlier studies21-23 had reported 
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anti-HCV positive infections, which are serological evidence of past or present HCV 
infection. In 2015, the Polaris Observatory was created to monitor and forecast the 
disease burden for hepatitis B and C.24 This analysis builds upon the previous efforts with 
an updated literature review and the addition of disease burden modeling to develop more 
accurate estimates of 2015 year-end viremic HCV prevalence at the country level and 
aggregated to the global level.  
 
Methods 
The present analysis represents the integration of a literature review, a Delphi process 
that used country expert interviews to identify missing inputs and to approve all 
inputs/outputs, and modeling to estimate 2015 HCV prevalence. The details of the data 
collection, scoring of data sources, Delphi process and modeling, beyond the description 
in this section, are summarized in the Supplement. 
 
Systematic Literature Review and Data Quality Scoring 
Available published data between January 1, 2000 and March 31, 2016 were identified 
through searches of PubMed, EMBASE, and non-indexed reports (Supplement, Sections 
3). Non-indexed government reports, personal communication with country experts, and 
additional studies identified through manual searches of references noted in publications 
were included when better data were not available. The scope of the analysis included all 
countries. Articles were scored based on how well they could be extrapolated to the 
general population, the study sample size, and the year of analysis.20  
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HCV Disease Burden Modeling and Delphi Process 
From a methodological perspective, the biggest difference between the present and 
previous analysis is the use of a Markov model to estimate the HCV prevalence in 2015. 
The reason for this addition is that HCV prevalence changes over time.25-27 After culling 
and scoring available studies, a Microsoft Excel® (version 2007)- based Markov-type 
model, described previously25-27, was populated with the highest-scoring epidemiological 
data for the country of interest (Supplement, Section 4).  
 
Approved: A Delphi process was used to gain country expert consensus and validate 
inputs (Supplement, Section 5). Experts were identified through HCV-related scientific 
contributions, or through referrals and recommendations from leading researchers. Two 
or more meetings were held to get consensus around input variables and outputs, and 
validate the outputs against available empirical data.  
 
Estimated: For countries where meeting with local experts could not be scheduled, 
published estimates were used. All published studies were reviewed and scored by two 
epidemiologists, and the highest scored study was used for modeling (Supplement, 
Section 7). When input other than prevalence rate was unavailable for a country, input 
was extrapolated from countries within the same Global Burden of Disease (GBD) 
region. 
 
Global and Regional HCV Viremic Prevalence and Genotype Distribution 
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GBD regional prevalence and genotype were calculated as the weighted average of the 
2015 outputs from approved and estimated models, and the regional rates were then 
applied to the 2015 populations of countries with missing data to estimate the global 
HCV prevalence and genotypes. Countries without a formal GBD designation were 
assigned an imputed GBD region (Supplement, Section 6).  
 
Sensitivity Analysis 
Uncertainty intervals and sensitivity analyses were conducted using Crystal Ball® 
(Release 11.1.3708.0), an Excel® add-in by Oracle®. Beta-PERT distributions 28 were 
used for all uncertain inputs. Monte Carlo simulation was used to estimate 95% 
uncertainty intervals (UI). It was assumed that prevalence uncertainty estimates in all 
countries were independent. The uncertainty range for each country was calculated based 
on range inputs for prevalence, transition rates, and mortality rate (Supplement, Sections 
2 & 7). These were used to calculate regional and global uncertainty ranges. For these 
estimates, two sources of uncertainty had to be taken into consideration – country level 
uncertainty in prevalence and their impact on the regional/global prevalence. The 2015 
country prevalence estimates and 95% UIs were consolidated and defined as assumption 
variables. A 1/0 switch was developed to include or exclude countries from the regional 
prevalence calculation, and was also defined as an assumption. A sensitivity analysis was 
run to identify countries that accounted for the greatest variation in the base global 
prevalence through their estimated prevalence uncertainty and their inclusion in regional 
averages.  
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Results 
Systematic Review – 9,177 studies were identified through PubMed (n = 4,556) and 
EMBASE (n = 4,621) with a publication date between January 1, 2013 and March 31, 
2016. Following the removal of duplicates (n = 2,408), 6,754 studies were selected for 
review and inclusion in the final analysis. When combined with prevalence studies 
published prior to 2013 20 and expert input, prevalence estimates were available for 113 
countries, accounting for 92% of the world’s population. Among all countries with a 
prevalence estimate, viremic rate was available for 81 countries, and age and gender 
distributions were available for 89 countries, accounting for 82% and 85% percent of the 
world’s 2015 population, respectively (Supplement, Section 7).  
 
The literature search for genotype data identified 11,342 studies through PubMed and 
EMBASE, and the results were combined with unpublished data provided by country 
experts. Genotype distribution was available for 115 countries (Table 1 and Supplement, 
Section 8), which accounted for 90% of the world’s 2015 population. 
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Modeled Countries – Models were built for 100 countries – the inputs and outputs for 59 
were approved by country experts and 41 were estimated using published data alone. To 
develop a model, at least one high quality prevalence study and one or more supporting 
inputs (i.e., age and gender, genotype, viremic rate, treatment rate) were necessary. The 
remaining countries had insufficient data to create a model.  
 
The evolution of the analysis is shown in Figure 1. Figure 1A shows countries with 
approved and estimated modeled-prevalence as well as countries whose prevalence was 
extrapolated from regional averages. For approved and estimated countries, the quality 
score of input prevalence data is shown in Figure 1B. The 2015 viremic HCV prevalence 
of the same countries is shown in Figure 1C, while the prevalence of all countries, 
including those with an extrapolated prevalence, is shown in Figure 1D. The number of 
HCV infections by country is shown in Figure 1E.  
 
The numerical prevalence and total infections for approved and estimated countries are 
shown in Table 1. The model input data for prevalence, quality score, year of prevalence 
estimate, uncertainty range, viremic rate, source of prevalence age distribution, and all 
corresponding references are included in Supplement, Section 7.  
 
Global Forecasts – The global prevalence of viremic HCV is estimated to be 0·96% 
(95% UI: 0·84-1·07%) in 2015, corresponding to 71 (62-79) million viremic infections. 
Regional estimates for HCV prevalence in 2015 are shown in Table 2. The countries 
which accounted for 80% of total global HCV infections are shown in Figure 2.  
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Sensitivity Analysis – The top ten country level uncertainties that made the largest 
contribution to the global uncertainty are shown in Figure 3. The top ten uncertainties 
listed account for 92% of the total variance in the global prevalence.  
 
A separate sensitivity analysis looked at the impact of excluding estimated countries from 
the analysis and basing the global prevalence on approved countries only. In this 
scenario, the estimated global prevalence would be 0·7% (0·6-0·8%) with a total number 
of HCV infections of 38 (34-41) million.  
 
Genotype Distribution – The HCV genotype distribution of the modeled countries is 
shown in Table 1. These distributions were based on published studies referenced in the 
Supplement, Section 8. The latter table contains data on data quality scores of the 
underlying study and sources for G1a/G1b breakout if they were not reported in the 
primary study. The estimated genotype distribution by GBD region is shown in Figure 4, 
while the data are combined with total viremic HCV infections by GBD region and 
shown in Figure 1F.  
 
Discussion 
The present analysis represents both an update to and significant expansion of previous 
efforts to quantify the HCV prevalence and disease burden. A Delphi process was used to 
complement a traditional systematic review by adding a level of validation through 
discussions with country experts. In total, 400 experts were consulted to approve the 
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inputs and outputs of 59 country models. This work is additionally unique in that it uses a 
disease burden model to forecast the 2015 year-end HCV prevalence, accounting for the 
impact of a changing population due to aging, treatment and cure, and mortality.  
 
The 2015 global prevalence estimate of 0·96% (0·84-1·07%) or 71 (62-79) million 
infections is substantially lower than previous estimates.22,23 Previous studies were based 
on older and higher prevalence estimates for China and India (Figure 5). However, the 
more recent studies17,29 show a much lower infection rate in each country. In addition, 
most studies are conducted in the adult population; however, when estimates are applied 
to a country’s total population, disease burden is overestimated. Finally, the earlier 
studies reported anti-HCV prevalence that is evidence of past or present infection (rather 
than active infections). Our previous estimate took all these factors into account for a 
global estimate of 80 (64-103) million viremic infections.20 Since the last study, we 
completed interviews in 59 countries, and Nigeria and Cameroon reported much lower 
HCV prevalence based on unpublished national studies. This reduced the overall 
prevalence in the region. In addition, the modeling took into consideration the impact of 
mortality (liver-related and all cause) and treatment. The overall impact was a reduction 
in the global prevalence estimate, which was still within the uncertainty intervals of our 
previous estimate.20 The current estimate does report a more narrow uncertainty range as 
a result of the updated methodology and incorporating country interviews. 
 
Modeling the prevalence captured the change in the epidemiology of the HCV infection.  
As shown in Figure 6, globally, the total number of viremic HCV infections has been 
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decreasing since 2007; however, there were significant variations between regions.  Of 
the modeled countries, ten showed a ≥10% growth in prevalence since 2007 due to 
foreign workforce from endemic countries (Qatar, and UAE), iatrogenic infections 
(Azerbaijan, India, Iraq, Syria, and Uzbekistan), and infections among people who inject 
drugs (Iran, Russia, and Latvia).  In most other countries, mortality (all cause and liver 
related) was higher than new infections leading to a decrease in total infections over the 
same period.  Historically, prevalence was increasing in every region until blood 
screening started in early to mid 1990’s.   
 
However, developing an accurate global estimate remains a problem due to lack and 
quality of data. Of 250 recognized countries in the world, HCV prevalence estimates 
were available for 113 countries (not all countries were modeled due to lack of available 
secondary data needed for a model). Globally, 91 countries have a population less than 
1·5 million and only eight of these countries reported their HCV prevalence. Sixty 
percent (n=92) of the countries with a larger population had HCV prevalence studies. Of 
these, 21 countries had studies with a quality score of 3, 49 had a quality score of 2, and 
22 had a quality score of 1 (Figure 1B, Supplement, Section 7). Thirteen of the countries 
with a quality score of 1 were in Europe and included Austria, Germany, Italy, Belgium, 
Portugal, Finland, and Norway and twenty were high income countries. Thus, the quality 
of the epidemiology data did not correlate with counties’ income and robust national 
surveillance study in the general population are needed to better quantify HCV burden. 
Larger countries had much larger impact on the global estimates.  China (quality score = 
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3), Pakistan (score = 3), India (score = 1), Egypt (score = 3), Russia (score = 2), and USA 
(score = 3) accounted for 51% of total HCV infections globally (Figure 2).  
 
The sensitivity analysis (Figure 3) illustrates the impact of uncertainties on the global 
prevalence. Of all the uncertainties considered, the uncertainty in the total number of 
infections in India had the largest impact on our forecast. If the total number of infections 
in India is 11·0 million, rather than 6·2 million, the global estimate would be 76·6 million 
infections instead of 71·1 million. This takes into account the additional infections in 
India as well as the impact of India’s prevalence on the regional prevalence, which is then 
applied to countries without data. Removing India’s prevalence completely and using the 
regional prevalence instead (for India and other countries in the region without data) was 
the third largest driver of uncertainty. The global prevalence would be 75·9 million in 
this case, since other countries in the region (with data) have a higher prevalence than 
India, and regional prevalence is dampened by India. A similar observation is made in 
Sub-Saharan Africa-Central region, where only the Central African Republic (prevalence 
0·3%) and Gabon (7·04%) had reported prevalence estimates. Removing the former from 
the analysis would result in Gabon being used for the regional average and an estimate of 
76·7 million infections globally (Figure 3). 
 
The prevalence range reported above does capture all uncertainties considered. Future 
revisions will most likely come from estimates for countries without reported studies 
(grey countries in Figure 1C), which included a large number of countries in Africa as 
well as some in Central and South America and Eastern Europe. As illustrated above, 
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country interviews can provide more recent unpublished prevalence estimates. To test the 
impact of having approved estimates, a sensitivity analysis was conducted where all 
estimated (non-approved) countries were removed from the analysis. In this scenario, the 
total estimated number of infections (globally) was 38 million. This result may be 
explained by a selection bias as a result of interviews being conducted in countries with a 
low prevalence. 
 
Overall, care was taken to minimize biases that could have the largest impact on the 
global estimate. In 59 countries, interviews with country experts were used to identify 
relevant unpublished data and approve inputs/outputs. Panel meetings run the risk of 
confirmation, observer, and recall bias; however, facilitator training and meeting 
structure were designed to minimize the impact of these biases. Over the course of the 
project, ten facilitators were trained to lead country interviews. Each meeting required 
two attendees, one facilitator, and one note-taker. After each meeting, the note-taker 
provided feedback on how to improve future facilitations. In addition, for all models, the 
data inputs, model calibration, and outputs were reviewed by a second independent 
epidemiologist before being incorporated into the global estimate. 
 
The genotype distribution, by region, did not change significantly (Figure 4) since the last 
study20 with the exception of further refinement of genotype 1 (G1). When G1a and G1b 
were not available in the highest scored study, secondary studies were used. This 
refinement was requested by experts since these sub-genotypes still show a different 
response rate to the available therapies. A new analysis was also added (Figure 1F) that 
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combined genotypes and total infections by region. At a global level, G1 dominated (44% 
of all infections), followed by G3 (25%) and G4 (15%). G1 dominated in high and high 
middle income countries (60% of all infections), while G3 (36%) was common in low 
middle income countries, and G4 (45%) was common in low income countries. This 
highlights the importance of pan-genotypic therapies for elimination of HCV. 
 
Many of the limitations of the original study20 were addressed here; however, there 
remained a number of limitations. As mentioned above, availability of data and the 
quality of available data limited the accuracy of the forecasts (especially in Sub-Sahara 
Africa). Ranges were used to address the uncertainty in the available data. In addition, in 
the modeled countries the treated population was segmented by genotype proportionally 
to the genotype distribution of the HCV infected population. If individuals with specific 
genotypes were treated preferentially, then the genotype distribution of the prevalent 
population could be different than what is forecasted here. The use of a model to forecast 
2015 HCV prevalence introduced another limitation – the accuracy of the model. When 
available, the outputs of the model were validated against empirical data to reduce errors 
due to the modeling.  However, another limitation was the uncertainty in empirical data.  
Two recent studies have shown that HCC cases are under-reported by 37-50% in Sweden 
and Melbourne, Australia.30,31  This would result in an underestimation of HCC cases by 
our models. 
 
There has been much discussion regarding the lower HCV prevalence estimates of our 
studies as compared to previous studies.22,23 It is important to point out that over half of 
 33 
the countries included in this analysis were reviewed and approved by experts in each 
country. We forecast a continual decline in total HCV infections as we move forward. In 
2015, an estimated 950,000 patients were treated for HCV, with two thirds of those 
treatments with direct acting anti-viral.24 An estimated 700,000 individuals achieved 
sustained viral response and were removed from the infected population. This accounts 
for only 1% of the total infected population who are treated and cured annually. 
However, as countries develop their national hepatitis elimination strategies and expand 
prevention, screening, and treatment, a more rapid decline in total viremic infections is 
forecasted. 
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Tables 
Table 1. Modeled 2015 HCV viremic prevalence/chronically infected population (all ages) and genotype 
distribution 
Region/ Country Viremic 
Prevalence in 2015i 
Viremic Population 
(000) in 2015i 
Genotypesii 
1a 1b 1c 1  
(Other) 
2 3 4 5 6 Mixed/ Other 
Asia Pacific, High Income            
Japan 0·7%  
(0·3%-0·8%) 
857  
(364-1,024) 
 64·8%   34·2%     1·0% 
Korea, Republic of 0·5%  
(0·3%-0·5%) 
231  
(148-261) 
3·0% 45·4%  4·3% 45·3% 0·8% 0·2%  1·0%  
Asia, Central             
Armenia   5·2% 36·2%  1·7% 18·9% 38·0%     
Azerbaijan 1·9%  
(1·3%-2·1%) 
190  
(125-212) 
2·9% 64·2%   6·7% 26·0% 0·2%    
Georgia 4·2%  
(3·0%-4·2%) 
165  
(120-169) 
1·9% 37·6%   24·5% 34·3%    1·7% 
Kazakhstan 2·8%  
(1·9%-3·2%) 
508  
(334-572) 
2·5% 52·5%   10·0% 35·0%     
Mongolia 6·4%  
(4·3%-7·9%) 
194  
(131-237) 
 98·8%   1·2%      
Tajikistan    82·7%   5·8% 7·7%    3·8% 
Uzbekistan 4·3%  
(3·0%-5·0%) 
1,292  
(902-1,524) 
2·9% 64·2%   6·7% 26·0% 0·2%    
Asia, East             
China 0·7%  
(0·5%-0·8%) 
9,795  
(6,675-10,832) 
1·4% 56·8%   15·4% 8·7%   6·3% 11·4% 
Hong Kong 0·2%  
(0·1%-0·3%) 
15  
(6-22) 
4·3% 62·4%   3·2% 2·8%   27·4%  
Taiwan 2·1%  
(1·3%-3·7%) 
489  
(310-877) 
2·6% 45·5%  0·7% 39·5% 1·0% 0·2%  0·5% 10·1% 
Asia, South             
Afghanistan 0·5%  
(0·3%-0·8%) 
181  
(85-258) 
35·2% 2·8%    62·0%     
India 0·5%  
(0·4%-0·8%) 
6,245  
(4,748-10,957) 
9·0% 16·1%  3·3%  64·1% 7·3% 0·3%   
Nepal   11·3% 6·6%  21·4%  58·4%    2·4% 
Pakistan 3·8%  
(2·8%-3·9%) 
7,172  
(5,363-7,487) 
4·8% 1·2%  1·0% 3·8% 79·0% 1·6% 0·1% 0·1% 8·3% 
Asia, Southeast             
Cambodia 1·6%  
(0·9%-1·7%) 
257  
(147-272) 
 24·0%    20·0%   56·0%  
Indonesia 0·5%  
(0·2%-0·8%) 
1,289 
(443-2,046) 
25·6% 39·0%  3·0% 9·3% 9·4% 3·6%   10·0% 
Laos    4·4%       95·6%  
Malaysia 1·2%  
(0·8%-1·3%) 
382  
(240-405) 
   35·8% 0·7% 62·3% 0·7%  0·4%  
Myanmar   4·1% 6·9%   0·7% 39·3%   49·0%  
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Region/ Country Viremic 
Prevalence in 2015i 
Viremic Population 
(000) in 2015i 
Genotypesii 
1a 1b 1c 1  
(Other) 
2 3 4 5 6 Mixed/ Other 
Philippines 0·6%  
(0·3%-0·6%) 
614  
(353-651) 
70·7% 2·5%   26·4%  0·2%  0·2%  
Sri Lanka    46·9%   37·5%     15·6% 
Thailand 0·7%  
(0·4%-0·7%) 
463  
(255-487) 
4·4% 13·0%    47·8%   34·8%  
Vietnam 1·1%  
(0·6%-1·2%) 
1,066  
(580-1,116) 
30·0% 17·1%   1·1% 1·1%   50·8%  
Australasia             
Australia 1·0%  
(0·7%-1·0%) 
230  
(178-244) 
18·5% 15·7%  15·4% 5·6% 42·2% 1·3%  1·1% 0·2% 
New Zealand 1·0%  
(0·6%-1·3%) 
48  
(30-62) 
44·0% 11·0%   7·0% 35·0%   1·0% 2·0% 
Caribbean             
Cuba 0·3%  
(0·1%-0·7%) 
35  
(14-77) 
17·0% 81·0%        2·0% 
Dominican 
Republic 
0·6%  
(0·4%-1·0%) 
68  
(42-108) 
58·9% 19·4%  3·7% 9·6% 0·5% 0·2%   7·7% 
Guadeloupe 0·3%  
(0·2%-0·6%) 
1  
(1-3) 
   80·0%  20·0%     
Martinique   23·6% 56·7% 0·9%  6·9% 7·8% 3·6% 0·3% 0·3%  
Suriname       100·0%      
Europe, Central             
Albania   6·0% 50·0%   20·0% 8·0% 16·0%    
Bosnia and 
Herzegovina 
  4·0% 69·3%   4·0% 21·3% 1·3%    
Bulgaria 1·2% 
(0·7%-1·6%) 
87 
(46-122) 
5·3% 72·3%    11·6%    10·8% 
Croatia 0·6%  
(0·4%-0·7%) 
26  
(17-28) 
13·1% 37·4%  8·3% 2·2% 35·6% 3·4%    
Czech Republic 0·4%  
(0·2%-0·5%) 
43  
(22-49) 
13·2% 52·8%   0·5% 31·1% 2·4%    
Hungary 0·5%  
(0·3%-0·6%) 
52  
(29-55) 
9·1% 79·9%  1·6% 0·9% 6·7% 1·7% 0·1%   
Macedonia      55·4%  44·6%     
Montenegro   19·6% 35·0%   1·1% 24·7% 19·6%    
Poland 0·5%  
(0·4%-0·6%) 
184  
(136-224) 
2·0% 83·0%   0·1% 10·0% 4·9%    
Romania 2·5%  
(1·8%-2·6%) 
547  
(397-566) 
5·4% 92·6%    0·8% 1·2%    
Serbia      57·9%% 3·7% 23·2% 6·7%   8·5% 
Slovakia 0·6%  
(0·4%-0·7%) 
33  
(20-37) 
   89·9% 1·5% 6·6% 0·5%  0·5% 1·0% 
Slovenia 0·3% 
(0·2%-0·3%) 
6  
(4-7) 
6·9% 8·2%  53·0% 2·1% 29·3% 0·4% 0·1%   
Europe, Eastern             
Belarus   5·0% 53·2%   2·5% 25·7% 13·6%    
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Region/ Country Viremic 
Prevalence in 2015i 
Viremic Population 
(000) in 2015i 
Genotypesii 
1a 1b 1c 1  
(Other) 
2 3 4 5 6 Mixed/ Other 
Estonia 1·4%  
(0·9%-1·6%) 
18  
(12-20) 
1·0% 71·7%   3·0% 24·2%     
Latvia 2·2%  
(1·4%-2·6%) 
43  
(28-50) 
46·1% 4.3%  13·4% 3·6% 31·9% 0·7%    
Lithuania 1·1%  
(0·7%-1·3%) 
33  
(20-39) 
2·1% 69·3%  3·8% 5·6% 19·2%     
Russia 3·3%  
(2·3%-3·5%) 
4,748 
(3,238-4,960) 
2·1% 52·8%   8·1% 36·3% 0·1%   0·6% 
Ukraine   1·6% 42·1%   1·6% 28·8% 0·8%   25·1% 
Europe, Western             
Austria 0·2%  
(0·1%-0·4%) 
21  
(6-30) 
20·0% 52·0%   5·0% 19·0% 4·0%    
Belgium 0·6%  
(0·2%-0·7%) 
64  
(23-75) 
 50·0%  9·0% 6·0% 19·0% 14·0% 2·0%   
Denmark 0·3%  
(0·3%-0·3%) 
19  
(14-20) 
34·0% 12·0%   8·0% 43·0% 3·0%    
Finland 0·4%  
(0·3%-0·5%) 
23  
(16-26) 
10·2% 11·6%  3·3% 11·4% 48·8% 0·9% 0·1% 0·1% 13·6% 
France 0·3%  
(0·1%-0·3%) 
194 
(93-222) 
14·8% 29·7%  15·3% 9·1% 19·7% 9·2% 2·0% 0·2%  
Germany 0·3%  
(0·1%-0·4%) 
205  
(90-313) 
25·0% 33·0%  4·0% 6·4% 27·4% 3·3% 0·2% 0·2%  
Greece 1·1%  
(0·7%-1·5%) 
132  
(82-169) 
11·5% 28·4% 0·2% 5·1% 7·0% 34·0% 13·9%    
Iceland 0·3%  
(0·2%-0·4%) 
1  
(1-1) 
41·1% 1·8%   0·8% 55·3% 1·0%    
Ireland 0·6%  
(0·4%-0·9%) 
30  
(20-42) 
42·0% 14·0%   4·0% 39·0% 1·0%    
Israel 1·2%  
(0·7%-1·3%) 
100  
(60-103) 
12·0% 57·0%   8·0% 20·0% 3·0%    
Italy 1·1%  
(0·7%-2·7%) 
680 
(455-1,641) 
11·0% 44·0%  3·0% 15·0% 10·0% 7·0%   10·0% 
Luxembourg 0·9%  
(0·6%-1·0%) 
5  
(3-6) 
   55·3% 4·3% 33·6% 6·4%    
Malta 0·3%  
(0·2%-0·4%) 
1  
(1-2) 
45·0% 15·0%   1·0% 37·0% 2·0%    
Netherlands 0·1%  
(0·0%-0·2%) 
16  
(5-26) 
14·8% 15·6%  18·8% 9·7% 29·3% 10·5%   1·3% 
Norway 0·4%  
(0·3%-0·5%) 
21  
(15-24) 
18·0% 18·0%  4·0% 9·0% 50·0% 1·0%    
Portugal 0·8%  
(0·7%-1·1%) 
89  
(74-120) 
42·7% 21·4%  4·0% 1·3% 17·9% 12·5%   0·2% 
Spain 0·8%  
(0·3%-1·2%) 
386  
(159-557) 
24·0% 53·5%   2·0% 8·2% 9·7%   2·5% 
Sweden 0·4%  
(0·3%-0·4%) 
38  
(28-43) 
40·0% 10·0%   20·0% 30·0%     
Switzerland 1·0%  
(0·6%-1·1%) 
78  
(45-87) 
26·0% 26·0%   8·5% 29·2% 10·3%    
United Kingdom 0·3%  
(0·1%-0·3%) 
189  
(91-211) 
24·4% 11·9%  8·8% 7·3% 43·8% 3·8%    
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Region/ Country Viremic 
Prevalence in 2015i 
Viremic Population 
(000) in 2015i 
Genotypesii 
1a 1b 1c 1  
(Other) 
2 3 4 5 6 Mixed/ Other 
Latin America, Andean            
Peru 0·5%  
(0·3%-0·6%) 
167  
(99-182) 
74·0% 12·0%   2·0% 10·0%    2·0% 
Latin America, Central            
Colombia 0·8%  
(0·6%-0·9%) 
409  
(272-436) 
5·7% 82·8%   8·5% 2·8%     
Mexico 0·4%  
(0·3%-0·5%) 
532  
(304-557) 
45·4% 24·9%   21·8% 7·2% 0·3% 0·1%  0·0% 
Panama 0·3%  
(0·2%-0·3%) 
12  
(7-14) 
          
Venezuela 0·4%  
(0·2%-0·4%) 
118  
(59-126) 
37·0% 26·0%  0·4% 33·0% 4·0%     
Latin America, Southern            
Argentina 0·8%  
(0·3%-1·2%) 
326  
(144-490) 
20·3% 38·1%  0·8% 21·7% 17·8% 1·3%    
Chile 0·3%  
(0·2%-0·5%) 
57 
(31-94) 
7·9% 72·7%   2·0% 16·5% 0·6% 0·3% 0·1%  
Latin America, Tropical            
Brazil 0·9%  
(0·6%-0·9%) 
1,787  
(1,293-1,896) 
31·0% 33·4%  0·4% 4·6% 30·2% 0·2% 0·1%   
North Africa/Middle East            
Algeria 1·0%  
(0·3%-1·7%) 
388  
(140-674) 
1·4% 86·2%  1·2% 8·5% 0·9% 1·2% 0·2%  0·5% 
Bahrain 1·2%  
(0·8%-1·3%) 
17  
(11-18) 
14·1% 21·1%  1·6% 3·9% 15·6% 25·0%   18·8% 
Egypt 6·3%  
(4·5%-6·7%) 
5,625  
(4,007-6,044) 
 4·0%  6·0%   90·0%    
Iran 0·2%  
(0·2%-0·3%) 
199  
(129-226) 
39·7% 12·1%  1·3% 1·4% 27·7% 0·9%   16·9% 
Iraq 0·2%  
(0·2%-0·3%) 
85  
(60-97) 
1·4% 12·9%    17·1% 52·9%   15·7% 
Jordan 0·3%  
(0·1%-0·4%) 
25  
(11-29) 
23·1% 19·2%     57·7%    
Kuwait      15·0% 2·5% 2·5% 80·0%    
Lebanon 0·2%  
(0·1%-0·4%) 
8  
(3-18) 
6·6% 40·4%   3·7% 14·1% 33·8% 1·4% 0·1%  
Libya 0·7%  
(0·5%-0·7%) 
42  
(32-43) 
4·2% 6·4%  6·9% 7·0% 7·4% 14·6% 0·0%  53·5% 
Morocco 0·8%  
(0·5%-0·9%) 
263  
(190-328) 
6·5% 40·3%   41·6% 1·0% 0·6% 0·1%  10·0% 
Oman 0·4%  
(0·3%-0·4%) 
16  
(12-18) 
5·5% 30·0%  10·1% 2·1% 32·6% 16·5%   3·2% 
Palestine   18·5% 9·8%     64·1%   7·6% 
Qatar 1·6%  
(1·3%-1·8%) 
38  
(30-40) 
1·9% 10·7%  3·6% 0·9% 10·3% 72·4% 0·1%   
Saudi Arabia 0·3%  
(0·2%-0·9%) 
105  
(79-189) 
   38·6% 3·6% 5·2% 52·6%    
Syria 3·0%  554  3·4% 18·8%  6·3% 0·8% 1·8% 59·0% 10·0%   
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Region/ Country Viremic 
Prevalence in 2015i 
Viremic Population 
(000) in 2015i 
Genotypesii 
1a 1b 1c 1  
(Other) 
2 3 4 5 6 Mixed/ Other 
(1·3%-3·5%) (245-653) 
Tunisia 0·9%  
(0·2%-1·1%) 
108 
(25-123) 
5·1% 76·6%   5·1% 3·7% 7·3%   2·2% 
Turkey 0·6%  
(0·3%-1·0%) 
492  
(271-763) 
12·9% 80·4%   1·5% 3·7% 1·5%    
United Arab 
Emirates 
1·3%  
(0·5%-1·6%) 
131  
(50-159) 
5·4% 9·4%  25·6% 2·2% 35·0% 22·0%    
Yemen 0·8%  
(0·5%-0·9%) 
211 
(143-258) 
          
North America, High Income            
Canada 0·6%  
(0·4%-0·7%) 
212 
(136-246) 
36·5% 21·5%  6·1% 14·1% 20·2% 0·3%   1·3% 
Puerto Rico 1·0%  
(0·6%-1·6%) 
36  
(23-60) 
39·8% 27·1%  15·2% 12·1% 3·8% 1·8%  0·2%  
United States 0·9%  
(0·7%-1·2%) 
2,936  
(2,231-3,826) 
46·2% 26·3%   10·7% 8·9% 6·3%  1·1% 0·5% 
Oceania             
Papua New Guinea 1·2%  
(0·9%-4·2%) 
94  
(70-328) 
          
Samoa 0·1%  
(0·1%-0·2%) 
 0·2 
(0·1-0·4) 
          
Sub-Saharan Africa, Central            
Central African 
Republic 
0·3%  
(0·2%-0·4%) 
16  
(11-18) 
    8·6% 8·6% 82·8%    
Congo, Democratic 
Republic of the 
      3·2%  96·8%    
Equatorial Guinea      35·0% 1·7% 3·3% 60·0%    
Gabon 7·0%  
(5·1%-7·3%) 
124  
(90-129) 
   5·8% 2·2%  92·0%    
Sub-Saharan Africa, East            
Burundi 1·0%  
(0·8%-4·0%) 
120  
(93-459) 
5·6%     1·7% 92·7%    
Ethiopia 0·6%  
(0·4%-0·7%) 
647  
(410-726) 
8·8% 2·7%  2·0% 13·5% 9·5% 60·0%   3·5% 
Kenya 0·2%  
(0·1%-0·3%) 
115  
(42-126) 
10·0%    90·0%      
Madagascar 0·2%  
(0·2%-0·3%) 
56  
(39-81) 
 52·9%   47·1%      
Mozambique   27·8% 22·2%    22·2%  27·8%   
Sub-Saharan Africa, Southern            
South Africa 0·7%  
(0·4%-0·9%) 
356  
(227-441) 
2·3% 22·1%  7·1% 1·2% 12·6% 12·4% 35·7%  6·7% 
Sub-Saharan Africa, West            
Burkina Faso 1·3% 
(1·0%-1·4%) 
247  
(189-256) 
3·1% 9·4%   56·3% 15·6% 3·1%   12·5% 
Cameroon 0·7%  
(0·5%-0·8%) 
164  
(117-184) 
   40·0% 20·0%  40·0%    
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Region/ Country Viremic 
Prevalence in 2015i 
Viremic Population 
(000) in 2015i 
Genotypesii 
1a 1b 1c 1  
(Other) 
2 3 4 5 6 Mixed/ Other 
Chad 1·1%  
(0·8%-1·3%) 
162  
(111-184) 
   7·7% 7·7%  84·6%    
Gambia, The 0·8%  
(0·5%-1·3%) 
17  
(10-27) 
   19·4% 58·1% 6·5%    16·1% 
Ghana 1·4%  
(1·1%-3·4%) 
399  
(305-944) 
0·1% 0·2%  12·8% 87·0%      
Guinea-Bissau      1·8% 98·2%      
Nigeria 1·4%  
(1·0%-1·4%) 
2,553  
(1,902-2,651) 
   82·3% 5·9% 7·4% 4·4%    
i 2015 year-end estimate is a model output projection based on historic data 
ii Genotype distribution data are either taken from the literature or based on regional averages in the absence of country-specific data
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Table 2. Regional prevalence and number of infected individuals (all ages) 
Regions Viremic HCV  
Prevalence (95% UI) 
Population  
(Millions) 
Viremic HCV Infected 
(Millions) (95% UI) 
Asia Pacific, High Income 0·6% (0·3%-0·7%) 183 1·1 (0·6-1·3) 
Asia, Central 3·6% (2·8%-3·9%) 88 3·2 (2·5-3·4) 
Asia, East 0·7% (0·5%-0·8%) 1,439 10·5 (7·3-11·6) 
Asia, South 0·9% (0·7%-1·3%) 1,742 15·3 (12·3-22·7) 
Asia, Southeast 0·7% (0·5%-0·8%) 654 4·7 (3·2-5·2) 
Australasia 1·0% (0·8%-1·0%) 29 0·3 (0·2-0·3) 
Caribbean 0·5% (0·4%-0·8%) 45 0·2 (0·2-0·4) 
Europe, Central 1·0% (0·8%-1·0%) 118 1·2 (0·9-1·2) 
Europe, Eastern 3·3% (2·1%-3·4%) 206 6·7 (4·2 -7·0) 
Europe, Western 0·5% (0·4%-0·8%) 426 2·3 (1·9-3·2) 
Latin America, Andean 0·5% (0·3%-0·6%) 59 0·3 (0·2-0·3) 
Latin America, Central 0·5% (0·4%-0·5%) 247 1·3 (0·9-1·3) 
Latin America, Southern 0·6% (0·3%-0·9%) 64 0·4 (0·2-0·6) 
Latin America, Tropical 0·9% (0·6%-0·9%) 211 1·8 (1·3-2·0) 
North Africa/Middle East 1·7% (1·4%-1·9%) 498 8·5 (6·8-9·2) 
North America, High Income 0·9% (0·7%-1·1%) 362 3·2 (2·4-4·0) 
Oceania 1·1% (0·8%-3·7%) 11 0·1 (0·1-0·4) 
Sub-Saharan Africa, Central 2·1% (0·1%-6·9%) 115 2·4 (0·1-8·0) 
Sub-Saharan Africa, East 0·5% (0·4%-0·7%) 425 2·1 (1·6-2·9) 
Sub-Saharan Africa, Southern 0·7% (0·4%-0·9%) 76 0·5 (0·3-0·7) 
Sub-Saharan Africa, West 1·3% (1·1%-1·4%) 399 5·1 (4·3-5·7) 
Total 1·0% (0·8%-1·1%) 7,397 71·1 (62·5-79·4) 
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Figures 
Figure 1. Evolution of country HCV prevalence estimates (end of 2015) 
A. Countries with approved and estimated models and extrapolated prevalence  
Model Status
Extrapolated
Estimated
Approved
 
B. Data quality among countries with approved or estimated models 
 
C. 2015 Viremic prevalence among countries with approved or estimated models  
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D. Viremic prevalence all countries 
  
E. Number of viremic infected all countries 
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F. HCV genotype and total infected by GBD region 
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Figure 2. Countries accounting for 80% of the total viremic HCV infections 
 
 
Figure 3. Sensitivity analysis of global viremic infections – all ages (top 10) 
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Figure 4. Genotype distribution by GBD region 
 
Figure 5. Comparison of this and previous HCV prevalence estimates 
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Figure 6.  Change in viremic HCV prevalence by GBD Region 
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